Asset Details
Do you wish to reserve the book?
A high-risk papillomavirus 18 E7 affibody-enabled in vivo imaging and targeted therapy of cervical cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
A high-risk papillomavirus 18 E7 affibody-enabled in vivo imaging and targeted therapy of cervical cancer
Do you wish to request the book?
A high-risk papillomavirus 18 E7 affibody-enabled in vivo imaging and targeted therapy of cervical cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
A high-risk papillomavirus 18 E7 affibody-enabled in vivo imaging and targeted therapy of cervical cancer
2019
Overview
High-risk papillomavirus (HPV) is one of the major reasons for cervical cancer, causing most lethal gynecologic malignancies worldwide. For cervical cancer progression, oncogene E7 plays vital roles and is used as one of the major targets for cervical tumor diagnosis and treatment. In the clinic, successful treatment of cervical cancer relies on diagnosing the disease at an early stage, where a late-stage diagnosis usually led to treatment failure. In this work, we designed and purified an HPV18 E7 oncogene targeting affibody, named as Z
HPV18E7
, for in vitro and in vivo imaging and targeted treatment of cervical cancer. In vitro, Z
HPV18E7
showed a specific targeting effect against an HPV18 positive cell line; as a contrast, the affibody did not target the HPV18 negative cell line. In vivo, we tested the bio-distribution of the affibody in mice bearing cervical cancer. The whole animal imaging analysis indicated the affibody-targeted tumor tissue specifically with 10 min after injection, and the affibody reached the highest level at tumor tissues 45 min after injection. At the 24th hour after injection, the affibody still maintained a certain level in tumor tissues compared to other organs. To test the therapeutic effect of this affibody, we modified the affibody (i.e., Z
HPV18E7
) with a clinically used anti-cancer agent (i.e.,
Pseudomonas exotoxin
). In a mice cervical cancer model, Z
HPV18E7
was able to deliver
Pseudomonas exotoxin
to tumor tissues effectively, showing great potential for cancer treatment. This study indicated that Z
HPV18E7
could be employed for in vitro imaging and targeted treatment of cervical cancer. Beyond the chemotherapeutic agent used in this work, the affibody could be extended for carrying other therapeutic agents for cervical cancer treatment.
Publisher
Springer Berlin Heidelberg,Springer,Springer Nature B.V
Subject
/ Antibodies, Viral - immunology
/ Antibodies, Viral - pharmacology
/ Biomedical and Life Sciences
/ Biotechnologically Relevant Enzymes and Proteins
/ Cancer
/ Cervix
/ Female
/ Humans
/ Methods
/ Mice
/ Microbial Genetics and Genomics
/ Organs
/ Papillomavirus E7 Proteins - immunology
/ Papillomavirus Infections - immunology
/ Papillomavirus Infections - therapy
/ tissues
/ Tumors
/ Uterine Cervical Neoplasms - therapy
We currently cannot retrieve any items related to this title. Kindly check back at a later time.